A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Caroline, Preeta
- Treatment of Myocardial Infarction by Stem Cell Based Therapy
Authors
1 Krupanidhi College of Pharmacy, Chikkabellandur, Carmelaram, Bangalore - 560 035, Karnataka, IN
Source
Journal of Pharmaceutical Research, Vol 16, No 1 (2017), Pagination: 4-13Abstract
Purpose: Recently myocardial infarction is one of the leading causes of death worldwide. Myocardial infarction leads to the serious consequences which cause increase in mortality and morbidity. In myocardial infarction there is permanent loss of cardiomyocytes which results an irreversible loss of cardiac function. Cardiac repair requires the replacement, restoration and regeneration of heart function. Conventional therapies such as revascularization, percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) prevent the additional damage to heart muscle and also reduce the risk of future heart attack. However, there is need to develop a new therapy to improve the infracted area after the myocardial infarction and also to lower the mortality rate.
Approaches: The data were collected from various sources like journal articles, internet, textbooks, related materials in library and databases such as Pubmed, Science Direct, Springer, Google Scholar and so on.
Findings: Stem cell-based therapy is found to be a much more promising therapy when compared to other available therapies. Stem cells therapy shows significantly improved heart function after myocardial infarction, therefore decline into heart failure.
Conclusion: Recently the interest is stem cell based therapies which provide the potential benefit and have ability to improve the cardiac function. In this review, we highlight the benefits of stem cells in cardiac repair.
Keywords
Stem Cells, Totipotent, Pluripotent, Multipotent, Myocardial Infarction.References
- Veronique L. R. Epidemiology of myocardial infarction. Medical Clinical of North America. 2007; 91(4):537 - 539.
- The PREMISE program,2015. Prevention of Recurrence of Myocardial Infarction and Stroke Study. World Health Organization. Country project.
- Upaganlawar A. Isoproterenol induced myocardial infarction. Protective Role of Natural Product. Journal of Pharmacology and Toxicology. 2011; 6(1):1-17.
- Ashton Faulkner. Stem Cell Therapy: A New Approach for Treatment of Myocardial Infarction. Stem Cell Research and Therapy. 2001; S1-004:4172-7633.
- Sheing-Tsung Kuo. Stem Cell Therapy for Acute Myocardial Infarction and Heart Failure- Past, Present and Future. Taiwan Society of Internal Medicine. 2009; 20:1-18.
- Gupta BD. An introduction to stem cells and debate surrounding them. Journal Indian Academy of Forensic Medicine. 2009; 31(3):267.
- ISSCR. International Society for Stem Cell Research. 2016.
- Anand Krishna K. Myocardial Infarction and stem cells. Journal of Pharmacy and BioAllied Science. 2011; 3(2):182-188.
- Acosta SA. Human Umbilical Cord Blood for Transplantation Therapy in Myocardial Infarction. Journal of Stem cell Research and Therapy. 2013 ; 4: 005.
- Risheen R. Stem Cell Therapy in Acute Myocardial Infarction. Journal of Clinical and Experimental Cardiology. 2012; S11-004:2155-9880.
- Frat C. Resident cardiac stem cells. Current Pharmaceutical Design. 2011; 17(30):3252-3257.
- Bradfute SB. Cardiac progenitor cells from adult myocardium: homing differentiation and fusion after infraction. Proceedings of the National Academy of Sciences of the United States. 2003; 100:12313-12318.
- Buckingham M.. Skeletal muscle stem cells. Current opinion in genetic and development. 2008; 18(4):330336.
- Shah V.K. Stem Cell Therapy in Acute Myocardial Infarction: A plot of Gold or Pandora's Box. Stem Cell International. 2011; 20:20-24.
- Wam M. In vivo self renewal of c-kit+ Sca-1+ Lin (low/-) hemopoietic stem cells. Journal of Immunology. 1996; 156(9):3207-3214.
- Spangrude GJ. Purification and characteri-zation of mouse hematopoietic stem cells. Science. 1999; 241(4861):58-62.
- Pittenger MF. Multilineage potential of adult human mesenchymal stem cel ls. Science. 1999; 284(5411):143-147.
- M. ichew M. “Expression of VEGFR-2 and AC133 by circulating human CD34 (+) Cells identifies a population of function endothelial precursors”. Blood. 2000; 95(3):952-958.
- Calvin CS. Current Stem Cell Delivery Method for Myocardial Repair. Biomedical Research International. 2013 ; 4:15.
- Howard T. Walpole. Option for Stem Cell Delivery in Cardiology. Cardiac Catheteri-zation Laboratory. 2014; 2(1):e707.
- Mummery CL. Challenges in using stem cell for cardiac repair. Science Translation Medicine. 2010;2:17.
- Halkos ME. Intravenous infusion of mesenchymal stem cell enhances regional perfusion and improves ventricular function in a porcine model of myocardial infarction. Basic Research in Cardiology. 2008; 103(6):525-536.
- Dib N. Recommendations for successful training on method of delivery of biologist for cardiac regeneration: a report of the International Society for Cardiovascular Translation Research. Journal of the American College of Cardiology. 2010; 3(3):265-275.
- Pilio G. Direct minimally invasive intramyo-cardial injection of bone marrow derived AC133+ stem cell in patient with refractory ischemia: preliminary result. Thoracic and Cardiovascular Surgeon. 2008; 56(2):7176.
- Grossman PM. Incomplete retention after direct myocardial injec t ion. Catheter i zat ion and Cardiovascular Intervention. 2002; 55(3):392-397.
- Mozid AM. Stem cell therapy for heart diseases. British Medical Bulletin. 2011; 98(1):143-159.
- Sherman W. Catheter based delivery of cells to the heart. Natural Clinical Practice Cardiovascular Medicine. 2006; 3(1):S57-S64.
- Thompson CA. Percutaneous transvenous cellular cardiomyoplasty: a novel nonsurgical approach for myocardial cell transplantation. Journal of the American College of Cardiology. 2003; 41(11):1964-1971.
- Siminiak T. Post infarction heart failure: surgical and trans-coronary-venous transplan-tation of autologous myoblast. Natural Clinical Practice Cardiovascular Medicine. 2006; 3(1):S46-S51.
- Saccheetti A. Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pig and chronic experimental myocardial ischemia. Journal of the American College of Cardiology. 2001; 37(6):1726-1732.
- Perin EC. Assessing myocardial viability and infract transmurality with left ventricular electromechanical mapping in patient with stable coronary artery disease: validation by delayed- enhancement magnetic resonance imaging. Circulation. 2002; 106(8):957-961.
- Widimsky P. Intracoronary Transplantation of bone marrow stem cells: background, technique and limitation. European Heart Journal Supplement. 2006; 8:H16-H22.
- Copland IB. Mesenchymal stromal cells for cardiovascular disease. Journal of Cardio-vascular Disease Research. 2011; 2(1); 3-13.
- Suzuki K. Development of a novel method for cell transplantation through the coronary artery. Circulation. 2000; 102(19):III359-III364.
- Yokoyama SI. A strategy of retrograde injection of bone marrow mononuclear cells into the myocardial for the treatment of ischemic heart disease. Journal of Molecular and Cellular Cardiology. 2006; 40(1):24-34.
- Vicario J. One year follow-up of transcoronary sinus administration of autologous bone marrow in patient with chronic ref ractory angina. Cardiovascular Revascularization Medicine. 2005; 6(3):99-107.
- Sui R. The current status of engineering myocardial tissue. Stem Cell Review and Report. 2011; 7(1):172180.
- Li Z. High- efficiency matrix modulus- induced cardiac differentiation of human mesenchymal stem cell inside a thermo sensitive hydrogel. Acta Biomaterialia. 2012; 8(10): 3586-3595.
- Miyahara Y. Monolayered mesenchymal stem cell repair scarred myocardium after myocardial infarction. Nature Medicine. 2006; 12(4):459-465.
- Hou D. Radio labeled cell distribution after intramyocardial, intracoronary and interstitial retrograde coronary venous delivery: implication for current clinical trials. Circulation. 2005; 112(9):I150-I156.
- Andrew J. Stem Cell Therapy for Cardiac Repair. Circulation. 2006; 114:339-352.
- Orlic D. Bone marrow cells regenerate infracted myocardium. Nature. 2001; 401:701-705.
- Olivares EL. Bone marrow stromal cells improve cardiac performance in healed infracted rat hearts. American Journal of Physiology. 2004; 287:H464-470.
- Schuster MD. Myocardial neovascularization by bone marrow angioblast results in cardiomyocyte regeneration. American Journal of Physiology. 2004; 287:H525-H532.
- Tuch BE. Stem cells- a clinical update. Australian Family Physician. 2006; 35(6):719-721.
- Mitsui K. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell. 2003; 113(5):631-642.
- He JQ. Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization. Circulation Research. 2003; 93(1):3239.
- Vanderlaan RD. Electrophysiological profiling of cardiomyocytes in embryonic bodies derived from embryonic stem cells. Circulation Research. 2003; 93(1):1-3.
- Vawda R. Stem cells therapies for perinatal brain injuries. Seminars in Fetal and Neonatal Medicine.2001; 12(4):259-272.
- Liu S. Mammary stem cells, self renewal pathways and carcinogenesis. Breast Cancer Research. 2005; 7(3):86-95.
- Rolletschek A. Embryonic stem cell-derived cardiac, neuronal and pancreatic cells as model systems to study toxicological effects. Toxicology Letter. 2004; 149(1-3): 369-391.
- Korbling M. Adult stem cells tissue repair- a new therapeutic concept. New England Journal of Medicine. 2003; 349(6):570-582.
- Alonso L. Stem cells in the skin: waste not, Wnt not. Genes development. 2003; 17(10):1189-1200.
- A Review on Drug Interactions in Oral Hypoglycemic Drugs by Mechanism of Cytochrome P450 Enzyme Inhibition
Authors
1 Krupanidhi College of Pharmacy, #12/1, Chikkabellandur, Carmelaram Post, Varthur Hobli , Bangalore - 560035, KA, IN
Source
Journal of Pharmaceutical Research, Vol 16, No 2 (2017), Pagination: 154-159Abstract
Purpose: Drug interaction is a phenomenon that has to be thoroughly investigated in order to avoid adverse effects. This review article highlights the drug interaction of oral hypoglycemics by mechanism of cytochrome P450 enzyme inhibition.
Approach: Published articles from PubMed and other sources were used to review and compile these drug interaction studies.
Findings: Drug interaction in oral hypoglycemics by mechanism of cytochrome P450 enzyme inhibition can increase the risk of hypoglycemia in diabetic patients and hence dose adjustments may be required.
Conclusion: These drug interaction studies are essential for patients suffering from diabetes mellitus as it prevents the risk of occurrence of hypoglycemia. This information is also important for the prescribing physicians as dose alteration or alternate drugs need to administered in case of concomitant administration of drugs in case of polypharmacy.
Keywords
Drug Interaction, CYP450 Enzyme, Oral Hypoglycemics, Food-Drug Interaction.References
- Mallet L, hypoglycemia A, Huang A. The challenge of managing drug interactions in elderly people. The Lancet. 2007 Jul 20;370(9582):185-91.
- lberti KG, Zimmet PF. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic medicine. 1998 Jul 1;15(7):539-53.
- Peart GF, Boutagy J, Shenfield GM. The metabolism of glyburide in subjects of known debrisoquin phenotype. Clinical Pharmacology & Therapeutics. 1989 Mar 1;45(3):277-84.
- Jönsson A, Karlsson MO, Melander A. Concentration‐effect relations of glibenclamide and its active metabolites in man: modelling of Pharmacokinetics and Pharmacodynamics. British journal of clinical pharmacology. 1997 Apr 1;43(4):373-81.
- Wensing G. Topics in clinical pharmacology: Glipizide: an oral hypoglycemic drug. The American journal of the medical sciences. 1989 Jul 1;298(1):69-71.
- Brian WR. Hypoglycemic agents, In: Levy RH, Thummel KE, Tranger WF, Haunsten PD, Eichelbaum M, eds. Metabolic drug interactions. Philadelphia: Lippincott Williams & Wilkins; 2000. 429-43.
- Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA, Dalton JT. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9* 3 allele. Pharmacogenetics and Genomics. 1999 Feb 1;9(1):71-80.
- Lamy PP. Classification of drug interactions. Drug Information Journal. 1972 Jan;6(1):99-107.
- Prescott LF. Drug interaction during absorption. Naunyn-Schmiedeberg's archives of pharmacology. 1977 Jan 1;297(1):S29-31.
- Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. European journal of pharmaceutical sciences. 2006 Apr 30;27(5):425-46.
- Lu Z, Zhang R, Diasio RB. Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5‐fluorouracil chemotherapy. Clinical Pharmacology & Therapeutics. 1995 Nov 1;58(5):512-22.
- Marchitti SA, Brocker C, Stagos D, Vasiliou V. Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert opinion on drug metabolism & toxicology. 2008 Jun 1;4(6):697-720.
- Wormhoudt LW, Commandeur JN, Vermeulen NP. Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. Critical reviews in toxicology. 1999 Jan 1;29(1):59-124.
- Willey JC, Coy E, Brolly C, Utell MJ, Frampton MW, Hammersley J, Thilly WG, Olson D, Cairns K. Xenobiotic metabolism enzyme gene expression in human bronchial epithelial and alveolar macrophage cells. American journal of respiratory cell and molecular biology. 1996 Mar;14(3):262-71.
- Tom Lynch, Amy Price. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76:3916.
- Shitara Y, Sato H, Sugiyama Y. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu. Rev. Pharmacol. Toxicol.. 2005 Feb 10;45:689-723.
- Krentz AJ, Bailey CJ. Oral antidiabetic agents. Drugs. 2005 Feb 1;65(3):385-411.
- Groop LC. Sulfonylureas in NIDDM. Diabetes care. 1992 Jun 1;15(6):737-54.
- Dornhorst A. Insulinotropic meglitinide analogues. The Lancet. 2001 Nov 17;358(9294):1709-16.
- Goldstein BJ. Current views on the mechanism of action of thiazolidinedione insulin sensitizers. Diabetes technology & therapeutics. 1999 Sep 1;1(3):267-75.
- Lebovitz HE. Alpha-glucosidase inhibitors. Endocrinology and metabolism clinics of North America. 1997 Sep 1;26(3):539-51.
- Thornberry NA, Gallwitz B. Mechanism of action of inhibitors of dipeptidylpeptidase4 (DPP-4). Best Practice & Research Clinical Endocrinology & Metabolism. 2009 Aug 31;23(4):479-86.
- Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. Journal of the American Pharmacists Association: JAPhA. 2008 Dec;49:S16-29.
- Reda TK, Geliebter A, Pi‐Sunyer FX. Amylin, food intake, and obesity. Obesity research. 2002 Oct 1;10(10):1087-91.
- Neumiller JJ, White JR, Campbell RK. Sodium-glucose co-transport inhibitors. Drugs. 2010 Mar 1;70(4):377-85.
- Hansen JM, Christensen LK. Drug interactions with oral sulphonylurea hypoglycaemic drugs. Drugs. 1977 Jan 1;13(1):24-34.
- Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmöller J. Effect of genetic polymorphisms in cytochrome P450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs. Clinical pharmacokinetics. 2005 Dec 1;44(12):1209-25.
- Li XQ, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug metabolism and disposition. 2004 Aug 1;32(8):821-7.
- Rajendra SV, Narsu L, Ramachandra Setty S. Influence of rabeprazole on antidiabetic effect of sulfonylureas in diabetic rats. Pharmacologyonline. 2008;3:1017-23.
- Hatanaka T. Clinical pharmacokinetics of pravastatin. Clinical pharmacokinetics. 2000 Dec 1;39(6):397-412.
- Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, Benet LZ, Sewing KF, Christians U. Comparison of cytochrome P-450dependent metabolism and drug interactions of the 3-hydroxy-3methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug metabolism and disposition. 1999 Feb 1;27(2):173-9.
- Transon C, Leemann T, Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. European journal of clinical pharmacology. 1996 May 1;50(3):209-15.
- Satyanarayana S, Chandrasekhar MS, Palakshi Gouda O, Eswar Kumar K. Drug-drug interaction between Pravastatin and Gliclazide in animal models. Scholarly Research Exchange. 2008 Sep 3;2008.
- Sahi J, Black CB, Hamilton GA, Zheng X, Jolley S, Rose KA, Gilbert D, LeCluyse EL, Sinz MW. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metabolism and Disposition. 2003 Apr 1;31(4):439-46.
- Chaitanya Gadiko , Prakash Pamu, Eswar Kumar Kilari. Effect of amiodarone on the pharmacodynamics of gliclazide in animal models. International Journal of Pharmacy and Pharmaceutical Sciences. 2013;5(4):290-93.
- Mastan SK, Kumar KE. Influence of atazanavir on the pharmacodynamics and pharmacokinetics of gliclazide in animal models. International Journal of Diabetes Mellitus. 2010 Apr 30;2(1):56-60.
- Kumar GN, Rodrigues AD, Buko AM, Denissen JF. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. Journal of Pharmacology and Experimental Therapeutics. 1996 Apr 1;277(1):423-31.
- Mastan SK, Kumar KE. Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models. Diabetology & metabolic syndrome. 2009 Oct 9;1(1):15.
- Mouly S, Lown KS, Kornhauser D, Joseph JL, Fiske WD, Benedek IH, Watkins PB. Hepatic but not intestinal CYP3A4 displays dose‐dependent induction by efavirenz in humans. Clinical Pharmacology & Therapeutics. 2002 Jul 1;72(1):1-9.
- Mastan S, Eswar Kumar K. Effect of ritonavir on the pharmacodynamics of gliclazide in animal models. Diabetologia Croatica. 2009;38(4):105-3.
- Brian WR, Srivastava PK, Umbenhauer DR, Lloyd RS, Guengerich FP. Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry. 1989 Jun;28(12):4993-9.
- Back DJ, Tjia JF, Karbwang J, Colbert J. In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. British journal of clinical pharmacology. 1988 Jul 1;26(1):23-9.
- Sugita OS, Sawada YA, Sugiyama Y, Iga TA, Hanano MA. Kinetic analysis of tolbutamide-sulfonamide interaction in rabbits based on clearance concept. Prediction of species difference from in vitro plasma protein binding and metabolism. Drug metabolism and disposition. 1984 Jan 1;12(1):131-8.
- Sugita O, Sawada Y, Sugiyama Y, Iga T, Hanano M. Effect of sulfaphenazole on tolbutamide distribution in rabbits: Analysis of interspecies differences in tissue distribution of tolbutamide. Journal of pharmaceutical sciences. 1984 May 1;73(5):631-4.
- Komatsu K, Ito K, Nakajima Y, Kanamitsu SI, Imaoka S, Funae Y, Green CE, Tyson CA, Shimada N, Sugiyama Y. Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. Drug Metabolism and Disposition. 2000 Apr 1;28(4):475-81.
- Hidaka M, Fujita KI, Ogikubo T, Yamasaki K, Iwakiri T, Okumura M, Kodama H, Arimori K. Potent inhibition by star fruit of human cytochrome P450 3A (CYP3A) activity. Drug metabolism and disposition. 2004 Jun 1;32(6):581-3.
- Hidaka M, Okumura M, Fujita KI, Ogikubo T, Yamasaki K, Iwakiri T, Setoguchi N, Arimori K. Effects of pomegranate juice on human cytochrome p450 3A (CYP3A) and carbamazepine pharmacokinetics in rats. Drug metabolism and disposition. 2005 May 1;33(5):644-8.
- Fujita KI, Hidaka M, Takamura N, Yamasaki K, Iwakiri T, Okumura M, Kodama H, Yamaguchi M, Ikenoue T, Arimori K. Inhibitory effects of citrus fruits on cytochrome P450 3A (CYP3A) activity in humans. Biological and Pharmaceutical Bulletin. 2003;26(9):1371-3.
- Hidaka M, Nagata M, Kawano Y, Sekiya H, Kai H, Yamasaki K, Okumura M, Arimori K. Inhibitory effects of fruit juices on cytochrome P450 2C9 activity in vitro. Bioscience, biotechnology, and biochemistry. 2008 Feb 23;72(2):40611.
- Nagata M, Hidaka M, Sekiya H, Kawano Y, Yamasaki K, Okumura M, Arimori K. Effects of pomegranate juice on human cytochrome P450 2C9 and tolbutamide pharmacokinetics in rats. Drug metabolism and disposition. 2007 Feb 1;35(2):302-5.
- Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs. American Journal of Cardiovascular Drugs. 2004 Sep 1;4(5):281-97.
- Sublingual Tablets and the Benefits of the Sublingual Route of Administration
Authors
1 Krupanidhi College of Pharmacy, #12/1, Chikkabellandur, Carmelaram Post, Varthur Hobli, Bangalore - 560035, KA, IN
Source
Journal of Pharmaceutical Research, Vol 16, No 3 (2017), Pagination: 257-267Abstract
Purpose: Sublingual drug delivery can be an alternative and better route when compared to oral drug delivery as sublingually administered dosage forms bypass hepatic metabolism. A rapid onset of pharmacological effect is often desired for some drugs, especially those used in the treatment of acute disorders. Sublingual tablets disintegrate rapidly and the small amount of saliva present is usually sufficient for achieving disintegration of the dosage form coupled with better dissolution and increased bioavailability.
Approach: Published articles from PubMed and other standard sources were utilized to review and compile an overview of sublingual tablets and the benefits of the sublingual route of administration.
Findings: Sublingual tablets were found to have better characteristics when compared to conventional dosage forms. Sublingually administered tablets achieved better bioavailability, rapid onset of action and better dissolution properties due to fast disintegration. The addition of super-disintegrants facilitated rapid disintegration and this approach can be used to treat acute disorders or emergency conditions.
Conclusion: Sublingual tablets or any sublingual dosage form can be used to achieve a rapid onset of action, better patient compliance and increased bioavailability. The sublingual route of administration can be used for drugs which undergo extensive first pass metabolism or degradation in the GIT. Drugs administered sublingually tend to have better bioavailability which correlates to dose reduction when compared to conventional oral tablets.
Keywords
Sublingual Tablets, Easy Self-Medication, Fast Disintegration, Increased Bioavailability.References
- Zhang H, Zhang J, Streisand JB. Oral mucosal drug delivery. Clin Pharmacokinet. 2002 Aug 1;41 (9):661-80.
- Ashraf VA. Considerations in Developing Sublingual Tablets—An Overview. Pharm Tech. 2014 Nov 2;38(11) 34-72.
- Squier CA, Wertz PW. Structure and function of the oral mucosa and implications for drug delivery. Drugs Phar Sci. 1996;74:1-26.
- Edgar WM. Saliva: its secretion, composition and functions. Br Dent J. 1992 Apr;172(8):305-12.
- Shojaei AH. Buccal mucosa as a route for systemic drug delivery: a review. J Pharm Pharm Sci. 1998 Jan 1;1(1):15-30.
- Thompson IO, Van der Bijl P, Van Wyk CW, Van Eyk AD. A comparative lightmicroscopic, electron-microscopic and chemical study of human vaginal and buccal epithelium. Arc Oral Bio. 2001 Dec 31;46(12):1091-8.
- Galey WR, Lonsdale HK, Nacht S. The in vitro permeability of skin and buccal mucosa to selected drugs and tritiated water. Jour Invest Derm. 1976 Dec 1;67(6):713-7.
- Harris D, Robinson JR. Drug delivery via the mucous membranes of the oral cavity. Jour Phar Sci. 1992 Jan 1;81(1):1-0.
- Home FD. Orange Book: approved drug products with therapeutic equivalence evaluations.
- Wu SG, Lin SL, Shiao WY, Huang HW, Lin CF, Yang YH. Comparison of sublingual captopril, nifedipine and prazosin in hypertensive emergencies during hemodialysis. Nephron. 1993 Jul 1;65(2):284-7.
- Fernández ML, Sánchez MH, Muñoz PP, Fernández NG. Management of addictions in the elderly from primary health care. Quality of life, caregivers and intervention for health improvement in aging Volume III. 2015: 573.
- John DN, Fort S, Lewis MJ, Luscombe DK. Pharmacokinetics and pharmacodynamics of verapamil following sublingual and oral administration to healthy volunteers. Br J Clin Pharmacol. 1992 Jun 1;33(6):623-7.
- Fort S, Lewis MJ, Luscombe DK, John DN. Preliminary investigation of the efficacy of sublingual verapamil in the management of acute atrial fibrillation and flutter. Br J Clin Pharmacol. 1994 May 1;37(5):460-3.
- Haegeli L, Rocca BL, Peter H, Wenk M, Pfisterer M, Drewe J, Krähenbühl S. Sublingual administration of furosemide: new application of an old drug. Br J Clin Pharmacol. 2007 Dec 1;64(6):804-9.
- McIntyre J, Robertson S, Norris E, Appleton R, Whitehouse WP, Phillips B, Martland T, Berry K, Collier J, Smith S, Choonara I. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. The Lancet. 2005 Jul 22;366(9481):205-10.
- Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith RJ, Ling W. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. New Eng Jour Med. 2003 Sep 4;349(10):949-58.
- Bayrak Z, Tas C, Tasdemir U, Erol H, Ozkan CK, Savaser A, Ozkan Y. Formulation of zolmitriptan sublingual tablets prepared by direct compression with different polymers: In vitro and in vivo evaluation. Euro Jour Pharm, Biopharm. 2011 Aug 31;78(3):499-505.
- Supervia A, Pedro-Botet J, Nogues X, Echarte JL, Minguez S, Iglesias ML, Gelabert A. Piroxicam fast-dissolving dosage form vs diclofenac sodium in the treatment of acute renal colic: a double-blind controlled trial. Br J Clin Pharmacol. 1998 Jan 1;81:27-30.
- Rawas-Qalaji MM, Simons FE, Simons KJ. Sublingual epinephrine tablets versus intramuscular injection of epinephrine: dose equivalence for potential treatment of anaphylaxis. JAllergy Clin Immunol Pract. 2006 Feb 28;117(2):398-403.
- Gu X, Simon KJ, Simons F. Is epinephrine administration by sublingual tablet feasible for the firts-aid treatmentof anaphylaxis? A proof-of-concept study Biopharm Drug Disp. 2002 Jul 1;23(5):213-6.
- Volterrani M, Rosano G, Coats A, Beale C, Collins P. Estrogen acutely increases peripheral blood flow in postmenopausal women. Am J Med Sci. 1995 Aug 1;99(2):119-22.
- Price TM, Blauer KL, Hansen M, Stanczyk F, Lobo R, Bates GW. Single-dose pharmacokinetics of sublingual versus oral administration of micronized 17βestradiol. Int J Gynaecol Obstet. 1997 Mar 1;89(3):340-5.
- Pedersen GK, Ebensen T, Gjeraker IH, Svindland S, Bredholt G, Guzman CA, Cox RJ. Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP. PloS one. 2011 Nov 1;6(11):e26973.
- Song JH, Nguyen HH, Cuburu N, Horimoto T, Ko SY, Park SH, Czerkinsky C, Kweon MN. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1644-9.
- Raghavan S, Östberg AK, Flach CF, Ekman A, Blomquist M, Czerkinsky C, Holmgren J. Sublingual immunization protects against Helicobacter pylori infection and induces T and B cell responses in the stomach. Am J Infect Control. 2010 Oct 1;78(10):4251-60.
- Tayel SA, Soliman II, Louis D. Formulation of ketotifen fumarate fast-melt granulation sublingual tablet. AAPS PharmSciTech. 2010 Jun 1;11(2):679-85.
- Beckett AH, Boyes RN, Triggs EJ. Kinetics of buccal absorption of amphetamines. J Pharm Sci Pharmacol. 1968 Feb 1;20(2):92-7.
- Ho NF, Higuchi WI. Quantitative interpretation of in vivo buccal absorption of nalkanoic acids by the physical model approach. Int J Pharm Sci Invent. 1971 Apr 1;60(4):537-41.
- Vora KR, Higuchi WI, Ho NF. Analysis of human buccal absorption of drugs by physical model approach. Int J Pharm Sci Invent. 1972 Nov 1;61(11):1785-91.
- Schanker LS. Physiological transport of drugs. Adv Drug Res. 1964;1:71.
- Sadoogh-Abasian F, Evered DF. Absorption of vitamin C from the human buccal cavity. Br J Nutr. 1979 Jul 1;42(01):15-20.
- Rathbone MJ, Hadgraft J. Absorption of drugs from the human oral cavity. Int J Pharm Sci Res. 1991 Aug 2;74(1):9-24.
- Evered DF, Sadoogh-Abasian F, Patel PD. Absorption of nicotinic acid and nicotinamide across human buccal mucosa invivo. Life sciences. 1980 Nov 3;27(18):1649-51.
- Evered DF, Mallett C. Thiamine absorption across human buccal mucosa invivo. Life sciences. 1983 Mar 21;32(12):1355-8.
- Roy SD, Flynn GL. Solubility behavior of narcotic analgesics in aqueous media: solubilities and dissociation constants of morphine, fentanyl, and sufentanil. Phar Res. 1989 Feb 1;6(2):147-51.
- Bredenberg S, Duberg M, Lennernäs B, Lennernäs H, Pettersson A, Westerberg M, Nyström C. In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. Eur J Pharm Sci. 2003 Nov 30;20(3):327-34.
- Riahi S, Beheshti A, Mohammadi A, Ganjali MR, Norouzi P. Partition coefficient prediction of a large set of various drugs and poisons by a genetic algorithm and artificial neural network. Jour Chi Chem Soc. 2008 Apr 1;55(2):345-55.
- Li NY, Li Y, Gorrod JW. Determination of partition coefficients and ionisation constants of(S)(-)-nicotine and certain metabolites. Med Sci Res. 1992;20(23).
- Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 1997 Jan 15;23(1-3):3-25.
- Al-Ghananeem AM, Malkawi AH, Crooks PA. Effect of pH on sublingual absorption of oxycodone hydrochloride. AAPS PharmSciTech. 2006 Mar 1;7(1):E163-7.
- Wehling F, Schuehle S, Madamala N, inventors; Cima Labs, Inc., assignee. Effervescent dosage form with microparticles. U S patent US 5,178,878. 1993 Jan 12.
- Nibha KP, Pancholi SS. An overview on: Sublingual route for systemic drug delivery. Adv Drug Deliv Rev. 2012 Apr;2:913-23.
- Reo JP, Fredrickson JK. Taste Masking Science and Technology Applied to Compacted Oral Solid Dosage Forms-Part 1. Amer Pharm Rev. 2002;5:8-15.
- Kannuri R, Challa T, Chamarthi H. Taste masking and evaluation methods for orodispersible tablets. Int Jour PharmInd Res. 2011;1(3):201-10.
- Morella AM, Pitman IH, Heinicke GW, inventors; FH Faulding & Co., Limited, assignee. Taste masked liquid suspensions. US patent US 6,197,348. 2001 Mar 6.
- Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013 May 16;368(20):1867-77.
- Bredenberg S, Duberg M, Lennernäs B, Lennernäs H, Pettersson A, Westerberg M, Nyström C. In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. Eur J Pharm Sci. 2003 Nov 30;20(3):327-34.
- Bredenberg S, Nyström C. In-vitro evaluation of bioadhesion in particulate systems and possible improvement using interactive mixtures. J Pharm Sci Pharmacol. 2003 Feb 1;55(2):169-77.
- Van Scoik KG, inventor; Abbott Laboratories, assignee. Solid pharmaceutical dosage in tablet triturate form and method of producing same. US patent US 5,082,667. 1992 Jan 21.
- Dobetti L, inventor; Eurand International SPA, assignee. Fast disintegrating tablets. US patent US 6,596,311. 2003 Jul 22.
- Okada M, Ikeda Y, Ono K, Kurazumi T, Kasai S, Imamori K, inventors; SSP Co., Ltd., assignee. Quickly soluble solid preparations. US patent US 6,455,053. 2002 Sep 24.
- Dobetti L. Fast-melting tablets: Developments and technologies. Phar Tech. 2001 Sep;25(9; SUPP):44-50.
- Doelker E. Pharmaceutical dosage forms: Tablets: HA Lieberman, L. Lachman and JB Schwartz (Eds.), in three volumes, 2nd edn., revised and expanded, Marcel Dekker, New York, NY, 1989–1990, 1990, 592–616–560 pp.,
- Chaudry IA, King RE. Migration of potent drugs in wet granulations. J Pharm Sci. 1972 Jul 1;61(7):1121-5.
- Goodhart FW, Gucluyildiz H, Daly RE, Chafetz L, Ninger FC. Stabilized compressed nitroglycerin tablets. J Pharm Sci. 1976 Oct 1;65(10):1466-71.
- Makino T, Yamada M, Kikuta J. Fast dissolving tablet and its production, 1993. Euro Patent.;553777:A2.
- Mahajan U, Parashar B, Sharma N, Jadhav Y, Musasvad S, Patil V. Fast dissolving tablet-An overview of formulation technology. Ind GloJour Phar Sci. 2012;2(2):157-66.
- Fu Y, Yang S, Jeong SH, Kimura S, Park K. Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies. Crit Rev Therap Drug Car Sys. 2004;21(6).
- Bayrak Z, Tas C, Tasdemir U, Erol H, Ozkan CK, Savaser A, Ozkan Y. Formulation of zolmitriptan sublingual tablets prepared by direct compression with different polymers: In vitro and in vivo evaluation. Euro Jour PharBiophar. 2011 Aug 31;78(3):499-505.
- Chang RK, Xiaodi G, Burnside BA, Couch RA. Fast-dissolving tablets. Pharm Tech. 2000;24(6):52-8.
- Di Costanzo MF. T-Mask Technologies. In:,proceedings of the 7th International Glatt Symposium, USA 1997 (pp. 1-9).
- Cousin G, Bruna E, Gendrot E, inventors; Laboratoires Prographarm, assignee. Rapidly disintegratable multiparticular tablet. US patent US 5,464,632. 1995 Nov 7.
- Murakami T. Rapidly disintegrating tablets with saccharides. InProc Int Symp Cont Bioact Mater 1999 (Vol. 26, pp. 855-856).
- Habib W, Khankari R, Hontz J. Fast-dissolve drug delivery systems. Crit Rev Therap Drug Car Sys. 2000;17(1).
- Sharma S, Gupta G. Formulation and characterization of fast-dissolving tablet of promethazine theoclate. Asi J pharm. 2008 Jan 1;2(1):70.
- Battu SK, Repka MA, Majumdar S, Rao Y M. Formulation and evaluation of rapidly disintegrating fenoverine tablets: effect of superdisintegrants. Drug Dev Ind Pharm. 2007 Jan 1;33(11):1225-32.
- El-Arini SK, Clas SD. Evaluation of disintegration testing of different fast dissolving tablets using the texture analyzer. Pharm Dev Tech. 2002 Jan 1;7(3):361-71.
- Dor PJ, Fix JA. In vitro determination of disintegration time of quick-dissolve tablets using a new method. Pharm Dev Tech. 2000 Jan 1;5(4):575-7.
- Bi YX, Sunada H, Yonezawa Y, Danjo K. Evaluation of rapidly disintegrating tablets prepared by a direct compression method. Drug Dev Ind Pharm. 1999 Jan 1;25(5):571-81.
- Narang N, Sharma J. Sublingual mucosa as a route for systemic drug delivery. Int J Pharm Pharm Sci. 2011;3(Suppl 2):18-22.
- Park JH, Holman KM, Bish GA, Krieger DG, Ramlose DS, Herman CJ, Wu SH. An alternative to the USP disintegration test for orally disintegrating tablets. Pharm Tech. 2008 Aug 2;32(8).
- Rawas-Qalaji MM, Estelle F, Simons R, Simons KJ. Fast-disintegrating sublingual tablets: effect of epinephrine load on tablet characteristics. AAPS Pharm Sci Tech. 2006 Jun 1;7(2):E72-8.
- Deepak S, Dinesh K, Mankaran S, Gurmeet S, Singh RM. Taste masking technologies: a novel approach for the improvement of organoleptic property of pharmaceutical active substance. Int Res J Pharm. 2012;3(4):108-6.
- Tahara Y, Toko K. Electronic tongues–a review. IEEE Sens J. 2013 Aug;13(8):300111.
- Hashimoto Y, Matsunaga C, Tokuyama E, Tsuji E, Uchida T, Okada H. The quantitative prediction of bitterness-suppressing effect of sweeteners on the bitterness of famotidine by sweetness-responsive sensor. Chem Pharm Bull. 2007;55(5):739-46.
- Shishu K, Kapoor VR. Development of taste masked oral formulation of ornidazole. Ind J Phar Sci. 2010 Mar;72(2):211.
- Singh GJ, Poochikian G. Development and approval of inhaled respiratory drugs: a US regulatory science perspective. InCont PulDrug Del 2011 (pp. 489-527). Springer New York.
- Bennett CL, Chen B, Hermanson T, Wyatt MD, Schulz RM, Georgantopoulos P, Kessler S, Raisch DW, Qureshi ZP, Lu ZK, Love BL. Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol. 2014 Dec 31;15(13):e594-605.
- Jacob S, Shirwaikar A. Preparation and evaluation of microencapsulated fast melt tablets of ambroxol hydrochloride. Ind J Pharm Sci. 2009;71(3):276.